# Vertex Pharmaceuticals (VRTX) — Earnings VRTX · NASDAQ · Stock Canonical page: https://www.lighthorse.io/tickers/vrtx/earnings ## Most recent quarter | Metric | Value | | --- | --- | | Fiscal period | Q2 2026 | | Period end | Jun 30, 2026 | | EPS actual | $4.73 | | EPS estimate | $4.74 | | EPS surprise | −0.23% | | Revenue surprise | +3.25% | | Revenue | $3.3B | | Revenue estimate | $3.2B | | Reported | Aug 3, 2026 | | SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/875320/000087532026000259/vrtx-20260630.htm) | | Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/90edcb75-f4b5-8a6d-f814-a92e034e7a40.html) | Vertex Pharmaceuticals reported Q2 2026 results on August 3, 2026. Earnings per share came in at $4.73, just below the $4.74 estimate by 0.23%. Revenue was $3.3 billion, above the $3.2 billion consensus. Compared with Q2 2025, EPS rose about 5% from $4.52 and revenue rose about 14% from $2.9 billion. Revenue grew steadily, from $8.9 billion in 2022 to $9.9 billion in 2023, $11.0 billion in 2024 and $12.0 billion in 2025. Q2 2026 set the revenue high in the table. Annual EPS was $14.89 in 2022 and $15.22 in 2023, then fell to $0.29 in 2024. That year included a loss of $12.83 per share in Q2 2024, the only loss in the table. Annual EPS recovered to $18.41 in 2025. First-half 2026 EPS of $9.20 is about 7% above a year earlier. The EPS high was $5.03, in Q4 2025. Over the last 20 quarters, Vertex topped the EPS estimate 14 times. Its largest beat was 16.87%, in Q1 2024. Vertex reported Q3 between October 27 and November 6 in each of the past five years. That points to late October or early November 2026 for the next report. It will show whether revenue growth carries on. ## Earnings history | Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual | | --- | --- | --- | --- | --- | --- | --- | | Q2 2026 | Aug 3, 2026 | $4.74 | $4.73 | -0.23% | $3.2B | $3.3B | | Q1 2026 | May 4, 2026 | $4.24 | $4.47 | 5.35% | $3.0B | $3.0B | | Q4 2025 | Feb 12, 2026 | $5.11 | $5.03 | -1.58% | $3.2B | $3.2B | | Q3 2025 | Nov 3, 2025 | $4.57 | $4.80 | 4.96% | $3.1B | $3.1B | | Q2 2025 | Aug 4, 2025 | $4.29 | $4.52 | 5.40% | $2.9B | $2.9B | | Q1 2025 | May 5, 2025 | $4.32 | $4.06 | -5.95% | $2.9B | $2.8B | | Q4 2024 | Feb 10, 2025 | $4.02 | $3.98 | -0.90% | $2.8B | $2.9B | | Q3 2024 | Nov 4, 2024 | $4.08 | $4.38 | 7.41% | $2.7B | $2.8B | | Q2 2024 | Aug 1, 2024 | −$11.63 | −$12.83 | -10.36% | $2.7B | $2.6B | | Q1 2024 | May 6, 2024 | $4.07 | $4.76 | 16.87% | $2.6B | $2.7B | | Q4 2023 | Feb 5, 2024 | $4.07 | $4.20 | 3.27% | $2.5B | $2.5B | | Q3 2023 | Nov 6, 2023 | $3.93 | $4.08 | 3.72% | $2.5B | $2.5B | | Q2 2023 | Aug 1, 2023 | $3.86 | $3.89 | 0.80% | $2.4B | $2.5B | | Q1 2023 | May 1, 2023 | $3.01 | $3.05 | 1.23% | $2.3B | $2.4B | | Q4 2022 | Feb 7, 2023 | $3.53 | $3.76 | 6.50% | $2.3B | $2.3B | | Q3 2022 | Oct 27, 2022 | $3.61 | $4.01 | 11.00% | $2.2B | $2.3B | | Q2 2022 | Aug 4, 2022 | $3.47 | $3.60 | 3.64% | $2.1B | $2.2B | | Q1 2022 | May 5, 2022 | $3.57 | $3.52 | -1.38% | $2.1B | $2.1B | | Q4 2021 | Jan 26, 2022 | $3.29 | $3.37 | 2.53% | $2.0B | $2.1B | | Q3 2021 | Nov 2, 2021 | $3.09 | $3.56 | 15.22% | $1.9B | $2.0B | ## Frequently Asked Questions ### When did Vertex Pharmaceuticals (VRTX) last report earnings? Vertex Pharmaceuticals last reported on Aug 3, 2026, covering fiscal Q2 2026. ### Did VRTX beat earnings estimates? No. Vertex Pharmaceuticals reported EPS of $4.73 for Q2 2026 against a $4.74 estimate — a 0.23% miss. ### How much revenue did VRTX report last quarter? Vertex Pharmaceuticals reported $3.3B in revenue for Q2 2026, against a consensus estimate of $3.2B. ## Similar Stocks - [CRSP](https://www.lighthorse.io/tickers/crsp) — CRISPR Therapeutics AG - Common Shares - [MRNA](https://www.lighthorse.io/tickers/mrna) — Moderna, Inc. - Common Stock - [LLY](https://www.lighthorse.io/tickers/lly) — Eli Lilly and Company Common Stock - [ABBV](https://www.lighthorse.io/tickers/abbv) — AbbVie Inc. Common Stock - [GOOG](https://www.lighthorse.io/tickers/goog) — Alphabet Inc. - Class C Capital Stock - [PFE](https://www.lighthorse.io/tickers/pfe) — Pfizer, Inc. Common Stock - [AMZN](https://www.lighthorse.io/tickers/amzn) — Amazon.com, Inc. - Common Stock - [AXSM](https://www.lighthorse.io/tickers/axsm) — Axsome Therapeutics, Inc. - Common Stock - [ISRG](https://www.lighthorse.io/tickers/isrg) — Intuitive Surgical, Inc. - Common Stock - [EDIT](https://www.lighthorse.io/tickers/edit) — Editas Medicine, Inc. - Common Stock --- Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance. This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness. Data provided by [AInvest](https://www.ainvest.com).